February 5, 2026

@michaelokun

When fats go wrong: lipid dysmetabolism in Parkinson’s disease. Lipid dysmetabolism refers to disruptions in how the body makes and uses fats that are essential for brain cell function, energy, membranes and signaling. De-Paula and colleagues describe in a new paper in Brain how genetic risk for Parkinson’s disease links to specific disruptions in lipid metabolism that may help drive disease biology. Key Points: • Genetic risk variants were linked to altered sphingolipids and fatty acids, pointing to lipid pathways as active players in Parkinson’s disease. • Changes in ‘acylcarnitines’ suggested impaired mitochondrial energy handling both in blood and brain tissue. • Integrated genetics, metabolomics and proteomics mapped a causal chain ranging from risk genes to lipid dysmetabolism and their relationship to features of Parkinson’s disease. My take: This work reframes Parkinson’s disease as not just a dopamine story, but also to think of it as a metabolic one. Lipids appear frequently entangled w/ genetics, mitochondria and alpha-synuclein biology which may open new ways to think about biomarkers and potential therapies. Here are 5 points that resonated w/ me: 1- Lipid changes may appear before classic motor symptoms, making them attractive early signals. 2- Mitochondrial energy problems show up repeatedly across Parkinson’s disease when we key in on the biology. 3- Blood based lipid signatures could someday help health care providers track risk or progression. 4- Genetic links strengthen the case that lipid dysmetabolism is not just a bystander effect. 5- Targeting lipid metabolism may represent a realistic and testable therapeutic direction for some folks. https://academic.oup.com/brain/advance-article/doi/10.1093/brain/awag039/8455019 #michaelokun #fixelinstitute #parkinson